AstraZeneca PLC, which is developing the drug alongside the University of Oxford, is a frontrunner in the global race for a COVID-19 vaccine.

The media reported that as part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, the company's standard review process was triggered and it voluntarily paused vaccination to allow review of safety data by an independent committee.

It was not immediately clear where the patient was, or the nature and severity of their illness. In the US, the company began enrolling 30,000 volunteers across dozens of sites on 31 August 2020.

Shares of AstraZeneca Pharma India have lost 16.14% in two trading sessions. The stock has surged 103.81% from its 52-week low of Rs 1,888 hit on 23 March 2020. It hit a 52-week high of Rs 4,970 on 8 September 2020.

AstraZeneca Pharma India's net profit fell 13.39% to Rs 18.63 crore on 5.3% decline in revenue to Rs 193.57 crore in Q1 June 2020 over Q1 June 2019.

AstraZeneca Pharma India is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease.

As of 30 June 2020, UK-based AstraZeneca Pharma holds 75% stake in AstraZeneca Pharma India.

Powered by Capital Market - Live News

Indoco Remedies Ltd, Bharat Dynamics Ltd, Redington India Ltd, Amber Enterprises India Ltd are among the other stocks to see a surge in volumes on NSE today, 08 September 2020.

Astrazeneca Pharma India Ltd registered volume of 10.12 lakh shares by 14:19 IST on NSE, a 6.75 fold spurt over two-week average daily volume of 1.50 lakh shares. The stock slipped 6.25% to Rs.4,268.05. Volumes stood at 5.52 lakh shares in the last session.

Indoco Remedies Ltd clocked volume of 6.15 lakh shares by 14:19 IST on NSE, a 6.36 times surge over two-week average daily volume of 96796 shares. The stock gained 2.64% to Rs.221.55. Volumes stood at 34209 shares in the last session.

Bharat Dynamics Ltd recorded volume of 40.09 lakh shares by 14:19 IST on NSE, a 5.87 times surge over two-week average daily volume of 6.83 lakh shares. The stock lost 13.63% to Rs.332.05. Volumes stood at 2.89 lakh shares in the last session.

Redington India Ltd notched up volume of 22.05 lakh shares by 14:19 IST on NSE, a 5.04 fold spurt over two-week average daily volume of 4.37 lakh shares. The stock rose 0.83% to Rs.115.05. Volumes stood at 2.18 lakh shares in the last session.

Amber Enterprises India Ltd witnessed volume of 4.71 lakh shares by 14:19 IST on NSE, a 4.54 times surge over two-week average daily volume of 1.04 lakh shares. The stock increased 3.13% to Rs.1,895.45. Volumes stood at 1.25 lakh shares in the last session.

Powered by Capital Market - Live News

AstraZeneca Pharma India has received import and market permission in Form CT-20 (marketing authorization) from the Drugs Controller General of India (DCGI) for Olaparib film-coated tablets 100 mg and 150 mg - additional indication.

Olaparib is additionally indicated as a monotherapy for treatment of adult patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations (germline and/or somatic) who have progressed following a prior new hormonal agent.

The DCGI permission paves way for the launch of Olaparib in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease.

The company posted a 13.39% fall in net profit to Rs 18.63 crore in Q1 June 2020 from Rs 21.51 crore in Q1 June 2019. Revenue from operations stood at Rs 193.57 crore in Q1 June 2020, falling 5.3% from Rs 204.56 crore in Q1 June 2019.

Powered by Capital Market - Live News

AstraZeneca Pharma India has appointment of Ankush Nandra as Non]Executive Director.

Powered by Capital Market - Live News